SRNE - Sorrento completes enrollment in Brazil-based mid-stage trial for COVID-19 therapy

SvetaZi/iStock via Getty Images Following the conclusion of the enrollment in the U.S.-based mid-stage trial, Sorrento Therapeutics ([[SRNE]] -0.6%) has finished the enrollment in its Phase 2 clinical trial of Abivertinib in hospitalized COVID-19 patients in Brazil.The randomized, double-blind, placebo-controlled study is designed to assess the safety and efficacy of TI-5656 (Abivertinib Maleate) in patients hospitalized with cytokine storm with a particular emphasis on the drug’s impact on reducing the inflammatory cytokine storm.Unlike the U.S. trial, the trial protocol in Brazil includes patients at earlier stages of the disease with a dosing regimen spanning only 7 days (compared to 14 days for more advanced patients in the US).“By combining our efforts in the US and Brazil” we could “most importantly, accelerate data generation for regulators to assess the use of Abivertinib in COVID-19 patients with the potential of seeking an emergency use request,” commented Henry Ji, CEO of Sorrento.Topline data are

For further details see:

Sorrento completes enrollment in Brazil-based mid-stage trial for COVID-19 therapy